Latest news and press releases about Dyadic International, Inc. (DYAI): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Dyadic International, Inc. operates as a U.S.-based biotechnology platform company, specializing in the development, production, and commercialization of enzymes and other proteins. Its core activities are underpinned by a patented and proprietary C1 platform, alongside other advanced technologies.
Price
| Price | $0.40 |
| Market Cap | $15M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -6.38 |
| EV / EBITDA | -3.14 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -2918.10% |
| Return on Invested Capital | -278.95% |
| Return on Assets | -116.60% |
| Gross Margin | 30.44% |
| Operating Margin | -213.59% |
| Net Margin | -219.50% |
Related companies: ANVS · ATHE · BCAB · CELU · ELUT · MAIA · PYPD
Explore sector: Healthcare · Biotechnology
More sections of DYAI: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks